Cargando…

Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials

INTRODUCTION: As the number of Alzheimer's disease (AD) prevention studies grows, many individuals will need to learn their genetic and/or biomarker risk for the disease to determine trial eligibility. An alternative to traditional models of genetic counseling and disclosure is needed to provid...

Descripción completa

Detalles Bibliográficos
Autores principales: Langlois, Carolyn M., Bradbury, Angela, Wood, Elisabeth M., Roberts, J. Scott, Kim, Scott Y.H., Riviere, Marie-Emmanuelle, Liu, Fonda, Reiman, Eric M., Tariot, Pierre N., Karlawish, Jason, Langbaum, Jessica B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944715/
https://www.ncbi.nlm.nih.gov/pubmed/31921963
http://dx.doi.org/10.1016/j.trci.2019.09.013
_version_ 1783485065031843840
author Langlois, Carolyn M.
Bradbury, Angela
Wood, Elisabeth M.
Roberts, J. Scott
Kim, Scott Y.H.
Riviere, Marie-Emmanuelle
Liu, Fonda
Reiman, Eric M.
Tariot, Pierre N.
Karlawish, Jason
Langbaum, Jessica B.
author_facet Langlois, Carolyn M.
Bradbury, Angela
Wood, Elisabeth M.
Roberts, J. Scott
Kim, Scott Y.H.
Riviere, Marie-Emmanuelle
Liu, Fonda
Reiman, Eric M.
Tariot, Pierre N.
Karlawish, Jason
Langbaum, Jessica B.
author_sort Langlois, Carolyn M.
collection PubMed
description INTRODUCTION: As the number of Alzheimer's disease (AD) prevention studies grows, many individuals will need to learn their genetic and/or biomarker risk for the disease to determine trial eligibility. An alternative to traditional models of genetic counseling and disclosure is needed to provide comprehensive standardized counseling and disclosure of apolipoprotein E (APOE) results efficiently, safely, and effectively in the context of AD prevention trials. METHODS: A multidisciplinary Genetic Testing, Counseling, and Disclosure Committee was established and charged with operationalizing the Alzheimer's Prevention Initiative (API) Genetic Counseling and Disclosure Process for use in the API Generation Program trials. The objective was to provide consistent information to research participants before and during the APOE counseling and disclosure session using standardized educational and session materials. RESULTS: The Genetic Testing, Counseling, and Disclosure Committee created a process consisting of eight components: requirements of APOE testing and reports, psychological readiness assessment, determination of AD risk estimates, guidance for identifying providers of disclosure, predisclosure education, APOE counseling and disclosure session materials, APOE counseling and disclosure session flow, and assessing APOE disclosure impact. DISCUSSION: The API Genetic Counseling and Disclosure Process provides a framework for large-scale disclosure of APOE genotype results to study participants and serves as a model for disclosure of biomarker results. The process provides education to participants about the meaning and implication(s) of their APOE results while also incorporating a comprehensive assessment of disclosure impact. Data assessing participant safety and psychological well-being before and after APOE disclosure are still being collected and will be presented in a future publication.
format Online
Article
Text
id pubmed-6944715
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-69447152020-01-09 Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials Langlois, Carolyn M. Bradbury, Angela Wood, Elisabeth M. Roberts, J. Scott Kim, Scott Y.H. Riviere, Marie-Emmanuelle Liu, Fonda Reiman, Eric M. Tariot, Pierre N. Karlawish, Jason Langbaum, Jessica B. Alzheimers Dement (N Y) Featured Article INTRODUCTION: As the number of Alzheimer's disease (AD) prevention studies grows, many individuals will need to learn their genetic and/or biomarker risk for the disease to determine trial eligibility. An alternative to traditional models of genetic counseling and disclosure is needed to provide comprehensive standardized counseling and disclosure of apolipoprotein E (APOE) results efficiently, safely, and effectively in the context of AD prevention trials. METHODS: A multidisciplinary Genetic Testing, Counseling, and Disclosure Committee was established and charged with operationalizing the Alzheimer's Prevention Initiative (API) Genetic Counseling and Disclosure Process for use in the API Generation Program trials. The objective was to provide consistent information to research participants before and during the APOE counseling and disclosure session using standardized educational and session materials. RESULTS: The Genetic Testing, Counseling, and Disclosure Committee created a process consisting of eight components: requirements of APOE testing and reports, psychological readiness assessment, determination of AD risk estimates, guidance for identifying providers of disclosure, predisclosure education, APOE counseling and disclosure session materials, APOE counseling and disclosure session flow, and assessing APOE disclosure impact. DISCUSSION: The API Genetic Counseling and Disclosure Process provides a framework for large-scale disclosure of APOE genotype results to study participants and serves as a model for disclosure of biomarker results. The process provides education to participants about the meaning and implication(s) of their APOE results while also incorporating a comprehensive assessment of disclosure impact. Data assessing participant safety and psychological well-being before and after APOE disclosure are still being collected and will be presented in a future publication. Elsevier 2019-11-06 /pmc/articles/PMC6944715/ /pubmed/31921963 http://dx.doi.org/10.1016/j.trci.2019.09.013 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Featured Article
Langlois, Carolyn M.
Bradbury, Angela
Wood, Elisabeth M.
Roberts, J. Scott
Kim, Scott Y.H.
Riviere, Marie-Emmanuelle
Liu, Fonda
Reiman, Eric M.
Tariot, Pierre N.
Karlawish, Jason
Langbaum, Jessica B.
Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials
title Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials
title_full Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials
title_fullStr Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials
title_full_unstemmed Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials
title_short Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials
title_sort alzheimer's prevention initiative generation program: development of an apoe genetic counseling and disclosure process in the context of clinical trials
topic Featured Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944715/
https://www.ncbi.nlm.nih.gov/pubmed/31921963
http://dx.doi.org/10.1016/j.trci.2019.09.013
work_keys_str_mv AT langloiscarolynm alzheimerspreventioninitiativegenerationprogramdevelopmentofanapoegeneticcounselinganddisclosureprocessinthecontextofclinicaltrials
AT bradburyangela alzheimerspreventioninitiativegenerationprogramdevelopmentofanapoegeneticcounselinganddisclosureprocessinthecontextofclinicaltrials
AT woodelisabethm alzheimerspreventioninitiativegenerationprogramdevelopmentofanapoegeneticcounselinganddisclosureprocessinthecontextofclinicaltrials
AT robertsjscott alzheimerspreventioninitiativegenerationprogramdevelopmentofanapoegeneticcounselinganddisclosureprocessinthecontextofclinicaltrials
AT kimscottyh alzheimerspreventioninitiativegenerationprogramdevelopmentofanapoegeneticcounselinganddisclosureprocessinthecontextofclinicaltrials
AT rivieremarieemmanuelle alzheimerspreventioninitiativegenerationprogramdevelopmentofanapoegeneticcounselinganddisclosureprocessinthecontextofclinicaltrials
AT liufonda alzheimerspreventioninitiativegenerationprogramdevelopmentofanapoegeneticcounselinganddisclosureprocessinthecontextofclinicaltrials
AT reimanericm alzheimerspreventioninitiativegenerationprogramdevelopmentofanapoegeneticcounselinganddisclosureprocessinthecontextofclinicaltrials
AT tariotpierren alzheimerspreventioninitiativegenerationprogramdevelopmentofanapoegeneticcounselinganddisclosureprocessinthecontextofclinicaltrials
AT karlawishjason alzheimerspreventioninitiativegenerationprogramdevelopmentofanapoegeneticcounselinganddisclosureprocessinthecontextofclinicaltrials
AT langbaumjessicab alzheimerspreventioninitiativegenerationprogramdevelopmentofanapoegeneticcounselinganddisclosureprocessinthecontextofclinicaltrials